Integration of novel agents into treatment of myeloma.
More than 150 years have passed since the first treatments of multiple myeloma were initiated. The past decade has seen a renaissance in the generation of therapies for myeloma as a result of heightened understanding of the molecular pathogenesis of the disease. This review article highlights the development and incorporation of the proteasome inhibitor bortezomib and the immunomodulatory drugs thalidomide and lenalidomide into standard myeloma treatment regimens. We also discuss the creation of multiple other myeloma agents currently in phase I/II testing and designed to target specific pathways in myeloma physiology.
Lee
Alfred Ian
AI
Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute Boston, MA 02115, USA.
Munshi
Nikhil C
NC
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D009101:Multiple Myeloma / Q000188:drug therapy*; D011480:Protease Inhibitors / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D007155:Immunologic Factors; D011480:Protease Inhibitors